Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non Muscle Invasive Bladder Cancer (BRIDGE)
NCT Number:
NCT05538663
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Bladder
Study Objectives:
To determine the event free survival (EFS) of BCG-naïve high grade non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical BCG vs GEMDOCE. To compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naïve high grade NMIBC patients receiving BCG and GEMDOCE.
Study Documents
(MUSC NetID required for document access)